JP2006508098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508098A5 JP2006508098A5 JP2004548931A JP2004548931A JP2006508098A5 JP 2006508098 A5 JP2006508098 A5 JP 2006508098A5 JP 2004548931 A JP2004548931 A JP 2004548931A JP 2004548931 A JP2004548931 A JP 2004548931A JP 2006508098 A5 JP2006508098 A5 JP 2006508098A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound according
- group
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- -1 methylenedioxy group Chemical group 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 230000003595 spectral effect Effects 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GVKXFVCXBFGBCD-TURJJOHXSA-N COC1OCC(C(CO)O)OC1Oc1cc(O[C@@]([C@@H]([C@H]([C@H]2O)C(OC)=O)c3ccccc3)([C@@]22O)c(cc3)ccc3OC)c2c(OC)c1 Chemical compound COC1OCC(C(CO)O)OC1Oc1cc(O[C@@]([C@@H]([C@H]([C@H]2O)C(OC)=O)c3ccccc3)([C@@]22O)c(cc3)ccc3OC)c2c(OC)c1 GVKXFVCXBFGBCD-TURJJOHXSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/291,863 | 2002-11-08 | ||
| US10/291,863 US6710075B2 (en) | 2000-07-05 | 2002-11-08 | Therapeutic compounds and methods |
| PCT/AU2003/001463 WO2004041812A1 (en) | 2002-11-08 | 2003-11-06 | Therapeutic compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508098A JP2006508098A (ja) | 2006-03-09 |
| JP2006508098A5 true JP2006508098A5 (cg-RX-API-DMAC10.html) | 2010-08-26 |
| JP4847014B2 JP4847014B2 (ja) | 2011-12-28 |
Family
ID=32312131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004548931A Expired - Fee Related JP4847014B2 (ja) | 2002-11-08 | 2003-11-06 | 治療化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1569928A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4847014B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2003277988A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2504999A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2004041812A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5249508B2 (ja) | 2006-11-06 | 2013-07-31 | 三菱重工業株式会社 | 軌道系交通システム |
| ES2743199T3 (es) * | 2011-06-16 | 2020-02-18 | Korea Res Inst Chemical Tech | Derivados de indanona, sales farmacéuticamente aceptables o isómeros ópticos de los mismos, método de preparación para los mismos y composiciones farmacéuticas que los contienen como ingrediente activo para prevenir o tratar enfermedades virales |
| WO2014092514A1 (ko) | 2012-12-14 | 2014-06-19 | 한국화학연구원 | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
| CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
| JP7592748B2 (ja) | 2020-04-20 | 2024-12-02 | ノバルティス アーゲー | 抗ウイルス１，３－ジ－オキソ－インデン化合物 |
| CN120590351A (zh) | 2020-04-20 | 2025-09-05 | 诺华股份有限公司 | 抗病毒素1,3-二氧代茚化合物 |
| CN115385924B (zh) * | 2022-10-06 | 2023-10-13 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19835325A1 (de) * | 1998-08-05 | 2000-02-10 | Bayer Ag | Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten |
| AUPQ866500A0 (en) * | 2000-07-05 | 2000-08-03 | Exgenix Operations Pty Ltd | Therapeutic compounds and methods |
-
2003
- 2003-11-06 EP EP03769069A patent/EP1569928A4/en not_active Withdrawn
- 2003-11-06 AU AU2003277988A patent/AU2003277988A1/en not_active Abandoned
- 2003-11-06 WO PCT/AU2003/001463 patent/WO2004041812A1/en not_active Ceased
- 2003-11-06 CA CA002504999A patent/CA2504999A1/en not_active Abandoned
- 2003-11-06 JP JP2004548931A patent/JP4847014B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4544446B2 (ja) | ｓＰＬＡ２阻害作用を有するピロロ［１，２−ｂ］ピリダジン誘導体 | |
| EP2069342B1 (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, leur preparation et leur application en therapeutique | |
| ES2330636T3 (es) | Derivados amida del acido 3-oxo-1,3-dihidro-indazol-2-carboxilico como inhibidores de la fosfolipasa. | |
| WO2004096806A1 (ja) | 縮合イミダゾール誘導体 | |
| CA2917965C (fr) | Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HU229314B1 (en) | Polymorphs of an epothilone analog | |
| EP3164393B1 (fr) | Dérivés de flavaglines | |
| JP2013522325A5 (cg-RX-API-DMAC10.html) | ||
| CA2753135A1 (fr) | Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique | |
| TW200906401A (en) | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | |
| JP2006508098A5 (cg-RX-API-DMAC10.html) | ||
| FR2917413A1 (fr) | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique | |
| WO2014020101A1 (fr) | Derives de griseofulvine | |
| EP1773835A2 (fr) | Derives de pyrido-pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| CN102807575B (zh) | 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用 | |
| CN119522098A (zh) | 用于治疗精神障碍的吡啶衍生物 | |
| ES2866324T3 (es) | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria | |
| RU2639875C2 (ru) | Производное фенила | |
| JP2005531602A5 (cg-RX-API-DMAC10.html) | ||
| JP3215850B2 (ja) | ハロアルコキシ基を含有するピロロ［３，２―ｃ］キノリン誘導体及び薬学的に許容されるその塩 | |
| JP2008531713A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2006101081A1 (ja) | ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの結晶及びその製造方法 | |
| JPH0560478B2 (cg-RX-API-DMAC10.html) | ||
| JPH08225534A (ja) | 免疫抑制シクロリグナン誘導体 | |
| US20090029975A1 (en) | 1,3-benzothiazinone derivative and use thereof |